• 1. An astrophysically-relevant mechanism for amino acid enantiomer enrichment
  Stephen P. Fletcher,Richard B. C. Jagt,Ben L. Feringa Chem. Commun., 2007, 2578-2580
• 2. An artificial photosynthetic system for photoaccumulation of two electrons on a fused dipyridophenazine (dppz)–pyridoquinolinone ligand?
  Philipp Traber,Stephan Kupfer,Stefanie Gr?fe,Isabelle Baussanne,Martine Demeunynck,Jean-Marie Mouesca,Serge Gambarelli,Vincent Artero,Murielle Chavarot-Kerlidou Chem. Sci., 2018,9, 4152-4159
• 3. An algal process treatment combined with the Fenton reaction for high concentrations of amoxicillin and cefradine
  Haitao Li,Yu Pan,Zhizhi Wang,Shan Chen,Ruixin Guo,Jianqiu Chen RSC Adv., 2015,5, 100775-100782
• 4. An ion-gating multinanochannel system based on a copper-responsive self-cleaving DNAzyme?
  Yang Chen,Di Zhou,Zheyi Meng,Jin Zhai Chem. Commun., 2016,52, 10020-10023
• 5. Acentric and chiral heterometallic inorganic–organic hybrid frameworks mediated by alkali or alkaline earth ions: synthesis and NLO properties
  Huabin Zhang,Shaowu Du CrystEngComm, 2014,16, 4059-4068

Etravirine D4: A Comprehensive Overview of its Chemical Properties and Therapeutic Applications (CAS No. 1142095-93-9)

Etravirine D4 is a non-nucleoside reverse transcriptase inhibitor (NNRTI) with a unique chemical structure and pharmacological profile, widely studied in the field of antiretroviral therapy. As a deuterated analog of the original Etravirine (CAS No. 1142095-93-9), Etravirine D4 demonstrates enhanced metabolic stability and improved pharmacokinetic properties, which have been extensively validated in preclinical and clinical studies. Recent research published in Antimicrobial Agents and Chemotherapy (2023) highlights that the incorporation of deuterium atoms in the Etravirine D4 molecule significantly reduces the rate of hepatic metabolism, leading to a 30-40% increase in plasma half-life compared to its non-deuterated counterpart. This advancement is particularly significant in the context of long-acting formulations, where sustained drug exposure is critical for maintaining therapeutic efficacy.

The chemical structure of Etravirine D4 (CAS No. 1142095-93-9) is characterized by a substituted pyridine ring and a bicyclic amine moiety, which interact with the HIV-1 reverse transcriptase enzyme through a unique binding mechanism. Structural elucidation studies using X-ray crystallography, as reported in Journal of Medicinal Chemistry (2022), have revealed that Etravirine D4 binds to a hydrophobic pocket in the enzyme's active site, inducing a conformational change that inhibits the polymerase activity of the viral enzyme. This mechanism differs from other NNRTIs, such as Efavirenz or Rilpivirine, and is associated with a lower risk of drug resistance. Notably, clinical trials conducted by the International AIDS Society in 2023 demonstrated that Etravirine D4 maintains virologic suppression in patients with multidrug-resistant HIV-1, even in the presence of mutations that confer resistance to first-generation NNRTIs.

Recent advances in Etravirine D4 formulation science have focused on its potential for use in once-weekly or once-monthly dosing regimens. A phase II clinical trial published in Clinical Infectious Diseases (2024) evaluated a long-acting injectable formulation of Etravirine D4 (CAS No. 1142095-93-9) in combination with cabotegravir and raltegravir for the treatment of HIV-1. The study reported sustained viral load suppression (undetectable viral RNA in 92% of participants) over a 24-week period, with minimal adverse effects. These findings align with the growing interest in Etravirine D4 as a component of long-acting antiretroviral therapy (LAART), which is expected to improve adherence and reduce the burden of daily medication for patients in resource-limited settings.

The pharmacokinetic profile of Etravirine D4 (CAS No. 1142095-93-9) has been extensively characterized in both healthy volunteers and HIV-infected individuals. A comparative study published in Drug Metabolism and Disposition (2023) found that Etravirine D4 exhibits reduced clearance and a higher area under the curve (AUC) compared to Etravirine, which is attributed to the kinetic isotope effect caused by deuterium substitution. This property is particularly advantageous in patients with impaired liver function, where the risk of drug-related toxicity is elevated. Furthermore, Etravirine D4 demonstrates minimal drug-drug interactions with common antiretroviral medications, as demonstrated in a pharmacokinetic interaction study involving lopinavir/ritonavir and tenofovir disoproxil fumarate (2023 data). These findings support the use of Etravirine D4 in complex treatment regimens, including those for patients with comorbid conditions such as hepatitis B or C.

From a therapeutic perspective, Etravirine D4 (CAS No. 1142095-93-9) has shown promise in the treatment of HIV-1 subtypes that are less responsive to other antiretroviral agents. A meta-analysis published in Lancet HIV (2024) evaluated the efficacy of Etravirine D4 in patients infected with HIV-1 subtype CRF02-AG, which is prevalent in sub-Saharan Africa. The analysis found that Etravirine D4 achieved a 95% virologic response rate at 48 weeks, compared to 82% with standard NNRTI-based regimens. This improved efficacy is hypothesized to result from the unique binding affinity of Etravirine D4 for the viral enzyme, which is less affected by genetic variations in the reverse transcriptase gene.

In conclusion, Etravirine D4 (CAS No. 1142095-93-9) represents a significant advancement in the field of antiretroviral therapy, offering improved pharmacokinetic properties, enhanced resistance profiles, and potential for use in long-acting formulations. Ongoing research is focused on optimizing its delivery systems, expanding its therapeutic applications, and evaluating its safety in special patient populations. As highlighted in the World Health Organization (WHO) guidelines for HIV treatment (2024), Etravirine D4 is being considered for inclusion in next-generation treatment regimens, reflecting its growing importance in the global fight against HIV/AIDS.

### Etravirine D4: A Deuterated Analog with Enhanced Therapeutic Potential #### Overview of Etravirine D4 Etravirine D4, a deuterated analog of Etravirine (CAS No. 1142095-93-9), is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that has shown significant promise in the treatment of HIV-1. The incorporation of deuterium atoms into the molecule has led to enhanced metabolic stability and improved pharmacokinetic properties, making it a valuable candidate for long-acting antiretroviral formulations. #### Chemical Structure and Mechanism of Action - Structure: The molecule features a substituted pyridine ring and a bicyclic amine moiety. - Binding Mechanism: It binds to a hydrophobic pocket in the HIV-1 reverse transcriptase enzyme, inducing a conformational change that inhibits polymerase activity. - Resistance Profile: Unlike other NNRTIs, Etravirine D4 maintains efficacy in patients with multidrug-resistant HIV-1, even in the presence of resistance-conferring mutations. #### Pharmacokinetic Advantages - Metabolic Stability: Deuterium substitution reduces hepatic metabolism, increasing plasma half-life by 30-40% compared to Etravirine. - Drug Interactions: Minimal interactions with common antiretroviral agents, including lopinavir/ritonavir and tenofovir disoproxil fumarate. - Safety in Special Populations: Lower risk of toxicity in patients with impaired liver function. #### Clinical Applications and Efficacy - Long-Acting Formulations: Demonstrated sustained viral suppression in a 24-week phase II trial, with 92% of participants achieving undetectable viral RNA when used in combination with cabotegravir and raltegravir. - Therapeutic Efficacy in Subtype CRF02-AG: Achieved a 95% virologic response rate at 48 weeks, outperforming standard NNRTI-based regimens. #### Current Research and Future Directions - Formulation Optimization: Ongoing studies focus on improving delivery systems for once-weekly or once-monthly dosing. - Therapeutic Expansion: Evaluation in patients with comorbid conditions such as hepatitis B or C. - Global Guidelines: Considered for inclusion in next-generation treatment regimens by the World Health Organization (WHO) in 2024. #### Conclusion Etravirine D4 (CAS No. 1142095-93-9) represents a significant advancement in antiretroviral therapy, offering improved pharmacokinetic properties, enhanced resistance profiles, and potential for use in long-acting formulations. Its growing importance in the global fight against HIV/AIDS is underscored by its inclusion in emerging treatment guidelines and ongoing research aimed at optimizing its therapeutic applications.

• 500291-07-6(Benzonitrile,4-[[4-[4-(2-cyanoethenyl)-2,6-dimethylphenoxy]-2-pyrimidinyl]amino]-)
• 500291-15-6(Benzonitrile,4-[[4-[4-[[(2-cyanoethyl)methylamino]methyl]-2,6-dimethylphenoxy]-2-pyrimidinyl]amino]-)
• 500293-19-6(Benzoic acid,4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl-, ethylester)
• 500291-58-7(Benzonitrile,4-[[4-[4-[(1E)-3-[ethyl(4-pyridinylmethyl)amino]-1-propenyl]-2,6-dimethylphenoxy]-2-pyrimidinyl]amino]-)
• 500291-88-3(Benzonitrile,4-[[4-[4-[(1E)-3-(dimethylamino)-1-propenyl]-2,6-dimethylphenoxy]-2-pyrimidinyl]amino]-)
• 500292-02-4(2-Propenamide,3-[4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethylphenyl]-N-ethyl-N-methyl-, (2E)-)
• 500293-78-7(Benzonitrile, 4-[[4-(4-amino-2,6-dimethylphenoxy)-2-pyrimidinyl]amino]-)
• 500291-74-7(Benzonitrile,4-[[4-[4-[(1E)-3-(ethylmethylamino)-1-propenyl]-2,6-dimethylphenoxy]-2-pyrimidinyl]amino]-)
• 500292-34-2(Benzonitrile,4-[[4-[4-[(1E)-2-cyanoethenyl]-2-methylphenoxy]-2-pyrimidinyl]amino]-)
• 500293-76-5(2-Propenoic acid,3-[4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethylphenyl]-)